Abstract 1912
Background
The overall benefit from systemic treatments in advanced STS remains modest despite advances in cancer therapies. PDX models may help as avatars in guiding individualized drug use decisions.
Methods
In this prospective single center trial, fresh tumors from patients (pts) with suspected or recently diagnosed STS were engrafted into immunodeficient mice avatars (TumorGraft; Champions Oncology) and tested against a number of standard or non-licensed agents. PDX drug sensitivity profiles were then compared with real-life treatment outcomes.
Results
Of 18 patients enrolled, 3 patients were excluded (consent withdrawal/non-sarcomas). Patient baseline characteristics are summarized in the table. Rate of engraftment was 40% (6/15 pts), while the median time from biopsy to availability of drug sensitivity profile was 379 days (186 – 421). In patients with available drug sensitivity profile (9 different drugs involving 6 pts), the mouse avatar correctly predicted the drug efficacy or lack thereof of drugs in 7 of 9 drug selection time-points (78%) and in 5 of 6 patients (83%).Table:
1718P Patient baseline characteristics
Item | Eligible patients (n = 15) | Engrafted patients (n = 6) |
---|---|---|
Median age (range) | 57 (23-76) | 57 (45-69) |
Gender (M:F) | 8:7 | 3:3 |
Subtype - Liposarcoma - Leiomyosarcoma -UPS -Others | 5 3 1 6 | 2 2 1 1 |
Conclusions
PDX avatars can accurately predict drug response in STS pts. The rate of engraftment and time taken to produce drug sensitivity profiles are limitations for using this platform in guiding treatment for individual patients in real time. Nonetheless, the high degree of clinical predictability of this PDX platform may offer therapeutic value for personalized oncology approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Albiruni Razak.
Funding
Mount Sinai Sarcoma Foundation.
Disclosure
G. Paris: Full / Part-time employment: champions oncology. M. Mancini: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Champions Oncology. A.R.R. Albiruni: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): Lilly; Advisory / Consultancy, Research grant / Funding (self): Merck; Research grant / Funding (self): CASI Pharmaceuticals; Research grant / Funding (self): Novartis; Research grant / Funding (self): Deciphera; Research grant / Funding (self): Kayopharm Therapeutics; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche/ Genentech; Research grant / Funding (self): Boston Biomedical; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): MedImmune; Research grant / Funding (self): Amgen; Research grant / Funding (self): GlaxoSmithKline; Research grant / Funding (self): Blueprint Medicines; Research grant / Funding (self): AbbVie; Research grant / Funding (self): Adaptimmune. All other authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract